Long-term efficacy and downstream mechanism of anti-annexinA2 monoclonal antibody (anti-ANX A2 mAb) in a pre-clinical model of aggressive human breast cancer-Reference-Cited by-同舟云学术

Long-term efficacy and downstream mechanism of anti-annexinA2 monoclonal antibody (anti-ANX A2 mAb) in a pre-clinical model of aggressive human breast cancer

Published:2016-04 Issue:1 Volume:373 Page:27-35
ISSN:0304-3835
Container-title:Cancer Letters
language:en
Short-container-title:Cancer Letters

Author:

Sharma Mahesh C.,Tuszynski George P.,Blackman Marc R.,Sharma Meena

Funder

Research Service of the Veterans Affairs Medical Center, Washington DC

Department of Defense Idea award

Department of Defense Concept award

Publisher

Elsevier BV

Subject

Cancer Research,Oncology

Reference87 articles.

1. Monoclonal antibody-based therapy strategies: providing options for the cancer patient;Milenic;Curr. Pharm. Des,2002

2. Bevacizumab: overview of the literature;Braghiroli;Expert Rev. Anticancer Ther,2012

3. Potent pleiotropic anti-angiogenic effects of TM601, a synthetic chlorotoxin peptide;Jacoby;Anticancer Res,2010

4. Phase II trial of bevacizumab and irinotecan in recurrent malignant glioma;Vredenburgh;Clin. Cancer Res,2007

5. Harms from breast cancer screening outweigh benefits if death caused by treatment is included;Baum;BMJ,2013

Cited by 26 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The intricate role of annexin A2 in kidney: a comprehensive review;Renal Failure;2023-11-13

2. Collagen-I influences the post-translational regulation, binding partners and role of Annexin A2 in breast cancer progression;Frontiers in Oncology;2023-10-24

3. METTL3‐mediated ANXA2 inhibition confers neuroprotection in ischemic stroke: Evidence from in vivo and in vitro studies;The FASEB Journal;2023-05-30

4. Annexin A2 promotes angiogenesis after ischemic stroke via annexin A2 receptor – AKT/ERK pathways;Neuroscience Letters;2023-01

5. Annexin A2 : The diversity of pathological effects in tumorigenesis and immune response;International Journal of Cancer;2022-05-06